EDMONTON, April 27 /CNW/ - Ceapro Inc. (TSX-V: CZO) today announced that Frost & Sullivan have awarded Ceapro the 2006 Product Innovation Award in recognition of CeaProve(R) the pioneering point-of-care diagnostic product for type 2 diabetes and pre-diabetes. "It is a great honour to receive such a prestigious international award," said Dr. Mark Redmond, Ceapro's President and CEO. "The recognition will help establish a global profile for Ceapro and focus attention on our CeaProve(R) technology. We are confident that CeaProve(R) is poised to make a significant contribution to international health and addressing the global diabetes epidemic." The Frost & Sullivan Award for Product Innovation is presented each year to the company that has demonstrated excellence in new products and technologies within their industry. The recipient company has shown innovation by launching a broad line of emerging products and technologies. The measurement criteria for the award include: << - Significance of new product - Competitive advantage of new product - Product innovation in terms of unique or revolutionary technology - Product acceptance in the marketplace - New product value-added services provided to customers - Number of competitors with similar product >> About Frost & Sullivan Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community, by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www.frost.com. About CeaProve(R) CeaProve(R) is a simple, cost effective, and rapid point-of-care tool to detect the elevated blood glucose levels indicative of pre-diabetic and diabetic conditions. CeaProve(R) consists of calibrated wafers made from a proprietary formulation of proteins, fats, and complex carbohydrates that are consumed with a glass of water after an overnight fast. A quick analysis of the blood, using one of many standard glucose meters presently on the market, provides an on-the-spot indication of elevated blood glucose levels. About Ceapro Inc. Ceapro Inc is a growth stage biotechnology company. Ceapro's core technology is the extraction of functional, active ingredients. We will continue to add value to our extracts by manufacturing medical and therapeutic products, support the use of our extracts in products for human and animal health and introduce health and wellness services employing our CeaProve(R) diagnostic technology. Ceapro shares trade on the TSX Venture Exchange under the symbol CZO. To learn more about Ceapro, visit our website at www.ceapro.com. Shares Outstanding: 37,098,670, Recent Close: $0.265. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or the accuracy of this news release. This release may contain forward-looking statements. Various factors could cause actual results to differ materially from those projected in forward-looking statements. Although the Company believes that the forward-looking statements contained herein are reasonable, it can give no assurance that the Company's expectations are correct. All forward-looking statements are expressly qualified in their entirety by this cautionary statement.
Ceapro receives prestigious international award
Earlier from Ceapro
- Ceapro announces 2005 financial results
- Ceapro announces Corporate Officer appointments
- Ceapro successfully closes $1.3 million financing
- Ceapro announces 2005 third quarter financial results
- Ceapro to present CeaProve(TM) at Canadian Diabetes Association conference
Later from Ceapro
- Ceapro announces 2006 first quarter financial results
- Ceapro Inc. - Annual General Meeting Webcast - June 1, 2006
- Ceapro named on Profit 100 list of Canada's fastest-growing companies
- Ceapro announces 2006 second quarter financial results
- Ceapro Reports Management Changes
Follow Ceapro into a list and get an email when it puts out news.
Follow Ceapro